Samsung Biologics is a global contract development and manufacturing organization (CDMO) providing end-to-end services for biologics, including cell line development, process development, and commercial manufacturing. The company offers contract manufacturing organization (CMO) and contract development organization (CDO) services, supporting clients from early clinical stages through commercial supply. Its product portfolio includes antibody-based therapeutics, antibody-drug conjugates (ADCs), mRNA, and cell and gene therapies. Samsung Biologics operates manufacturing facilities in Songdo, South Korea, and Rockville, Maryland, with regional offices in New Jersey, Boston, Tokyo, and Amsterdam. The company serves biopharmaceutical partners worldwide, with significant revenue generated in Europe and the United States. It utilizes proprietary platforms such as S-CHOice, S-Tensify, DEVELOPICK, and S-HiCon to enhance development and manufacturing capabilities. In 2025, the company completed a spin-off of its biosimilar business to Samsung Epix Holdings and announced the acquisition of Human Genome Sciences to expand its U.S. manufacturing footprint. Samsung Biologics also launched organoid-based research services to support early-stage drug discovery and precision screening.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Drug Manufacturers - Specialty & Generic Homepage samsungbiologics.com
Sector Healthcare IR page samsungbiologics.com/ir
Tags
biologics, cdmo, contract manufacturing, cell line development, antibody-drug conjugates, mrna, cell and gene therapy, aseptic fill-finish, organoid services, biopharmaceuticals, S-CHOice, S-Tensify, DEVELOPICK, S-HiCon, ExellenS, Samsung Organoid, Samsung Biologics America, Human Genome Sciences, PolyPeptide Group, Samsung Epix Holdings
Press page —

Metrics

Valuation  
Market cap ₩ 68.603T
Market cap (USD) $ 50.491B
P/E 40.88
PEG 1.33
P/BV 8.20
P/S 15.09
P/OCF 28.19
P/FCF 42.13
Dividend yield —
Turnover / mcap —
Returns  
ROE 19.4%
ROI 23.9%
ROIC 21.2%
Profit margin 39.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 30.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 4.557T 4.547T 3.695T 3.001T 1.568T 1.165T 701.592B 535.806B 464.629B 294.622B 91.278B
Net profit 1.784T 1.083T 857.691B 798.056B 393.589B 240.975B 202.904B 224.109B -96.972B -176.823B 1.905T
Free cash flow 856.067B 355.682B 671.158B -3.792B 48.343B 62.425B -161.581B -311.065B -344.303B -225.654B -505.84B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 1.709M 952.917K — — — — — — — — —
Price performance 12m 0.79 — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 75.6B 25.8B 122B 187B 218B 366B 733B 679B 1.17T 676B
↳ YoY growth +104.4% -65.9% +371.5% +53.7% +16.5% +68.1% +100.0% -7.3% +71.5% -42.0%
↳ 5y CAGR +42.6% +37.1% +95.3% +41.0% +44.2% +25.4%
Borrowings, current (KRW) 404B 139B 387B 402B 191B 160B 1.14T 1.39T 327B 320B
Borrowings, non-current (KRW) 439B — — — — 1.11T 965B 240B 1.01T 599B
Bonds payable (KRW) — — — — — — — — — 599B
Lease liabilities (KRW) — 0.00 0.00 15.9B 22.5B 18.2B 410B 282B 146B 8.37B
Cash and deposits (KRW) 230B 358B 17.6B 125B 28.9B 47.4B 891B 368B 391B 149B
Intangible assets (KRW) 14B 19B 20B 21.8B 23.3B 32.2B 5.96T 5.83T 5.57T 60.2B
Right-of-use assets (KRW) — 0.00 0.00 16.1B 24.2B 20.6B 455B 462B 464B 8.88B
Net debt (borrowings + leases - cash) (KRW) 209B -219B 369B 292B 185B 1.25T 658B 1.54T 1.1T 778B
Cash flow detail
Operating cash flow (KRW) -62.7B 150B -32.4B 10.2B 202B 455B 953B 1.67T 1.66T 2.25T
Purchases of property, plant and equipment (KRW) -163B -494B -279B -172B -140B -406B -957B -995B -1.3T -1.39T
Purchases of intangible assets (KRW) -5.18B -10.7B -5.81B -9.46B -8.9B -14.9B -52.4B -110B -74B -83.3B
Share buybacks (cash effect) (KRW) — — — — — — — 0.00 0.00 -92B
Interest paid (cash effect) (KRW) -24.4B -17B -23.4B -26.3B -15.6B -18.6B -33.9B -63.5B -62.1B -37.1B
Income taxes paid (cash effect) (KRW) 63.1M 150M -1.13B -42.1B -38.4B -42.4B -188B -319B -307B -602B
Free cash flow (OCF - PPE - intangibles) (KRW) -231B -355B -317B -171B 53.5B 33.4B -56.2B 561B 282B 773B
Income detail
Total comprehensive income (KRW) -177B -106B 221B 199B 244B 392B 805B 846B 1.07T 1.78T
Comprehensive income to owners (KRW) — — 221B 199B 244B 392B 805B 846B 1.07T 1.78T
Reported Jul 23, 2019 Mar 30, 2020 Mar 11, 2021 Mar 11, 2021 Mar 11, 2021 Mar 7, 2024 Mar 7, 2024 May 15, 2026 May 15, 2026 Aug 14, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

SAMSUNG BIOLOGICS (ticker 207940), listed in South Korea.

ETFs Holding SAMSUNG BIOLOGICS

ETF Weight in ETF Shares Market value As of
HELX 2.26% 702 $ 630.273K Jun 30, 2026
MKOR 1.13% 1,877 $ 1.685M Jun 30, 2026
TEMX 0.72% 108 $ 96.965K Jun 30, 2026
FFEM 0.50% 304 $ 312.856K Jul 31, 2026
RFEM 0.37% 278 $ 289.563K Jul 31, 2026
MEM 0.26% 162 $ 145.448K Jun 30, 2026
DEHP 0.23% 853 $ 929.007K Nov 12, 2026
FFGX 0.13% 71 $ 73.068K Jul 31, 2026
REMG 0.09% 110 $ 98.761K Jun 30, 2026
DFAE 0.08% 6,707 $ 7.305M Nov 12, 2026
DFSE 0.08% 411 $ 447.622K Nov 12, 2026
TIER 0.08% 26 $ 26.75K Jul 31, 2026
NTSE 0.08% 48 $ 43.096K Jun 30, 2026
DEXC 0.06% 139 $ 151.386K Nov 12, 2026
DFEM 0.05% 4,427 $ 4.821M Nov 12, 2026
AVEM 0.05% 12,109 $ 12.73M Nov 16, 2026
AVSE 0.04% 81 $ 85.155K Nov 16, 2026
AVXC 0.03% 102 $ 107.232K Nov 16, 2026
DFAX 0.01% 1,460 $ 1.59M Nov 12, 2026